Adenocarcinoma of the Appendix
Welcome,         Profile    Billing    Logout  
 32 Companies   47 Products   47 Products   42 Mechanisms of Action   1 Trial   177 News 


1234»
  • ||||||||||  alisertib (MLN8237) / Puma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) -  Jan 4, 2019   
    P1,  N=17, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017 Active, not recruiting --> Completed | N=42 --> 17 | Trial completion date: Dec 2019 --> Oct 2016 | Trial primary completion date: Dec 2018 --> Oct 2016
  • ||||||||||  veliparib (ABT-888) / AbbVie
    Enrollment closed, Combination therapy, BRCA Biomarker, PARP Biomarker:  Phase II ABT-888 With Cyclophosphamide (clinicaltrials.gov) -  Jan 3, 2019   
    P2,  N=29, Active, not recruiting, 
    Active, not recruiting --> Completed | N=42 --> 17 | Trial completion date: Dec 2019 --> Oct 2016 | Trial primary completion date: Dec 2018 --> Oct 2016 Recruiting --> Active, not recruiting
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer (clinicaltrials.gov) -  Dec 4, 2018   
    P3,  N=225, Completed, 
    Active, not recruiting --> Terminated Terminated --> Completed | N=3000 --> 225 | Trial primary completion date: Jan 2100 --> Nov 2016
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion date, Trial termination, Metastases:  Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers (clinicaltrials.gov) -  Nov 13, 2018   
    P1,  N=39, Terminated, 
    Terminated --> Completed | N=3000 --> 225 | Trial primary completion date: Jan 2100 --> Nov 2016 Trial completion date: Jan 2020 --> Jun 2017 | Active, not recruiting --> Terminated; Merck requested to change MK-3475 dosing schedule; PI decided to close instead
  • ||||||||||  Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date, Metastases:  Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver (clinicaltrials.gov) -  Feb 26, 2018   
    P1,  N=2, Terminated, 
    Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Apr 2017 | Trial completion date: Apr 2019 --> Aug 2017 | Initiation date: Jan 2016 --> Jan 2016; IRB study closure by investigator due to low enrollment
  • ||||||||||  Trial termination, Trial primary completion date, Metastases:  Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy (clinicaltrials.gov) -  Feb 7, 2018   
    P=N/A,  N=6, Terminated, 
    N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Apr 2017 | Trial completion date: Apr 2019 --> Aug 2017 | Initiation date: Jan 2016 --> Jan 2016; IRB study closure by investigator due to low enrollment Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2015; Low Accrual Rate
  • ||||||||||  Phase classification, Enrollment change, Trial termination, Trial primary completion date:  CINE-Cyst: Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions (clinicaltrials.gov) -  Jan 17, 2018   
    P=N/A,  N=10, Terminated, 
    Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Sep 2015; Low Accrual Rate Phase classification: P1 --> P=N/A | N=200 --> 10 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  alisertib (MLN8237) / Puma
    Trial primary completion date, Metastases:  Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) -  Jan 9, 2018   
    P1,  N=42, Active, not recruiting, 
    Phase classification: P1 --> P=N/A | N=200 --> 10 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial primary completion date, Metastases:  Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers (clinicaltrials.gov) -  Dec 12, 2017   
    P1,  N=39, Active, not recruiting, 
    Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Jan 2020 --> Jan 2017
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Phase classification, Metastases:  Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers (clinicaltrials.gov) -  Jun 29, 2017   
    P1,  N=39, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Phase classification: P1/2 --> P1
  • ||||||||||  dalantercept (ACE-041) / Merck (MSD)
    Trial completion, Trial primary completion date:  Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  May 31, 2017   
    P2,  N=28, Completed, 
    Phase classification: P1/2 --> P1 Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jan 2016
  • ||||||||||  trebananib (AMG 386) / Amgen
    Trial completion, Enrollment change, Trial primary completion date:  Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) -  May 4, 2017   
    P2,  N=35, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Jan 2016 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016